Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: Current epidemiology and clinical impact

Current Opinion in Infectious Diseases

Volumn 27, Issue 2, 2014, Pages 200-210

  Trecarichi, Enrico M ^a   Tumbarello, Mario ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

antimicrobial resistance; cancer; febrile neutropenia; Gram negative bacteria

Indexed keywords

AMIKACIN; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CANCER PATIENT; ENTEROBACTER; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEBRILE NEUTROPENIA; GRAM NEGATIVE BACTERIUM; HOSPITAL COST; HUMAN; INCIDENCE; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA; REVIEW; STENOTROPHOMONAS MALTOPHILIA; TREATMENT FAILURE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FEBRILE NEUTROPENIA; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; NEOPLASMS;

EID: 84896694664     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000038     Document Type: Review

References (56)

1. Wisplinghoff H, Cornely OA, Moser S, et al. Outcomes of nosocomial bloodstream infections in adult neutropenic patients: a prospective cohort and matched case-control study. Infect Control Hosp Epidemiol 2003; 24:905-911.
2. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003; 36:1103-1110.
3. Tumbarello M, Trecarichi EM, Caira M, et al., He.M.A.B.I.S. (Hematological Malignancies Associated Bacterial Infections Surveillance) Italy. Derivation and validation of a scoring system to identify patients with bacteremia and hematological malignancies at higher risk for mortality. PLoS One 2012; 7:e51612.
4. Montassier E, Batard E, Gastinne T, et al. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis 2013; 32:841-850.
5. Pagano L, Caira M, Rossi G, et al., Hema e-Chart Group, Italy. A prospective survey of febrile events in hematological malignancies. Ann Hematol 2012; 91:767-774.
6. Al-Tonbary YA, Soliman OE, Sarhan MM, et al. Nosocomial infections and fever of unknown origin in pediatric hematology/oncology unit: a retrospective annual study. World J Pediatr 2011; 7:60-64.
7. Aslan S, Citak EC, Yis R, et al. Bacterial spectrum and antimicrobial susceptibility pattern of bloodstream infections in children with febrile neutropenia: experience of single center in southeast of Turkey. Indian J Microbiol 2012; 52:203-208.
8. Baskaran ND, Gan GG, Adeeba K, Sam IC. Bacteremia in patients with febrile neutropenia after chemotherapy at a university medical center inMalaysia. Int J Infect Dis 2007; 11:513-517.
9. Cattaneo C, Casari S, Bracchi F, et al. Recent increase in enterococci, viridans streptococci, Pseudomonas spp. and multiresistant strains among haematological patients, with a negative impact on outcome. Results of a 3-year surveillance study at a single institution. Scand J Infect Dis 2010; 42:324-332.
10. Chen CY, Tsay W, Tang JL, et al. Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia. Epidemiol Infect 2010; 138:1044-1051.
11. Chong Y, Yakushiji H, Ito Y, Kamimura T. Cefepime-resistant Gram-negative bacteremia in febrile neutropenic patients with hematological malignancies. Int J Infect Dis 2010; 14 (S3):e171-e175.
12. El-Mahallawy HA, El-Wakil M, Moneer MM, Shalaby L. Antibiotic resistance is associated with longer bacteremic episodes and worse outcome in febrile neutropenic children with cancer. Pediatr Blood Cancer 2011; 57:283-288.
13. Ghosh I, Raina V, Kumar L, et al. Profile of infections and outcome in high-risk febrile neutropenia: experience from a tertiary care cancer center in India. Med Oncol 2012; 29:1354-1360.
14. Gudiol C, Bodro M, Simonetti A, et al. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect 2013; 19:474-479.
15. Lv H, Ning B. Pathogenesis of bloodstream infection in children with blood cancer. Exp Ther Med 2013; 5:201-204.
16. Huang CC, Wu CJ, Wang LR, et al. Antimicrobial susceptibility of bacteremic isolates from cancer patients with or without neutropenia at a medical center in southern Taiwan. J Microbiol Immunol Infect 2011; 44:376-381.
17. Irfan S, Idrees F, Mehraj V, et al. Emergence of carbapenem resistant Gram negative and vancomycin resistant Gram positive organisms in bacteremic isolates of febrile neutropenic patients: a descriptive study. BMC Infect Dis 2008; 8:80.
18. Kjellander C, Björkholm M, Cherif H, et al. Hematological: low all-cause mortality and low occurrence of antimicrobial resistance in hematological patients with bacteremia receiving no antibacterial prophylaxis: a singlecenter study. Eur J Haematol 2012; 88:422-430.
19. Kumar P, Medhekar A, Ghadyalpatil NS, et al. The effect of age on the bacteria isolated and the antibiotic-sensitivity pattern in infections among cancer patients. Indian J Cancer 2010; 47:391-396.
20. Mebis J, Jansens H, Minalu G, et al. Long-term epidemiology of bacterial susceptibility profiles in adults suffering from febrile neutropenia with hematologic malignancy after antibiotic change. Infect Drug Resist 2010; 3:53-61.
21. Miedema KG, Winter RH, Ammann RA, et al. Bacteria causing bacteremia in pediatric cancer patients presenting with febrile neutropenia: species distribution and susceptibility patterns. Support Care Cancer 2013; 21:2417-2426.
22. Prabhash K, Medhekar A, Ghadyalpatil N, et al. Blood stream infections in cancer patients: a single center experience of isolates and sensitivity pattern. Indian J Cancer 2010; 47:184-188.
23. Ram R, Farbman L, Leibovici L, et al. Characteristics of initial compared with subsequent bacterial infections among hospitalised haemato-oncological patients. Int J Antimicrob Agents 2012; 40:123-126.
24. Samonis G, Vardakas KZ, Maraki S, et al. A prospective study of characteristics and outcomes of bacteremia in patients with solid organ or hematologic malignancies. Support Care Cancer 2013; 21:2521-2526.
25. Schelenz S, Nwaka D, Hunter PR. Longitudinal surveillance of bacteraemia in haematology and oncology patients at a UK cancer centre and the impact of ciprofloxacin use on antimicrobial resistance. J Antimicrob Chemother 2013; 68:1431-1438.
26. Swati M, Gita N, Sujata B, et al. Microbial etiology of febrile neutropenia. Indian J Hematol Blood Transfus 2010; 26:49-55.
27. Tumbarello M, Spanu T, Caira M, et al. Factors associated with mortality in bacteremic patients with hematologic malignancies. Diagn Microbiol Infect Dis 2009; 64:320-326.
28. Cattaneo C, Quaresmini G, Casari S, et al. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother 2008; 61:721-728.
29. Poon LM, Jin J, Chee YL, et al. Risk factors for adverse outcomes and multidrug-resistant Gram-negative bacteraemia in haematology patients with febrile neutropenia in a Singaporean university hospital. Singapore Med J 2012; 53:720-725.
30. Safdar A, Rolston KV. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis 2007; 45:1602-1609.
31. Trecarichi EM, Tumbarello M, Spanu T, et al. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 2009; 58: 299-307.
32. Gudiol C, Tubau F, Calatayud L, et al. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother 2011; 66:657-663.
33. Kang CI, Chung DR, Ko KS, et al., Korean Network for Study of Infectious Diseases. Risk factors for infection and treatment outcome of extendedspectrum b-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann Hematol 2012; 91:115-121.
34. Kim SH, Kwon JC, Choi SM, et al. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum b-lactamase production and its impact on outcome. Ann Hematol 2013; 92:533-541.
35. Wang SS, Lee NY, Hsueh PR, et al. Clinical manifestations and prognostic factors in cancer patients with bacteremia due to extended-spectrum b-lactamase-producing Escherichia coli or Klebsiella pneumoniae. J Microbiol Immunol Infect 2011; 44:282-288.
36. Arnan M, Gudiol C, Calatayud L, et al. Risk factors for, and clinical relevance of, faecal extended-spectrum b-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microbiol Infect Dis 2011; 30:355-360.
37. Bhusal Y, Mihu CN, Tarrand JJ, Rolston KV. Incidence of fluoroquinoloneresistant and extended-spectrum b-lactamase-producing Escherichia coli at a comprehensive cancer center in the United States. Chemotherapy 2011; 57:335-338.
38. Calatayud L, Arnan M, Liñares J, et al. Prospective study of fecal colonization by extended-spectrum-beta-lactamase-producing Escherichia coli in neutropenic patients with cancer. Antimicrob Agents Chemother 2008; 52:4187-4190.
39. Jeddi R, Ghédira H, Ben Amor R, et al. Risk factors of septic shock in patients with hematologic malignancies and Pseudomonas infections. Hematology 2011; 16:160-165.
40. Caselli D, Cesaro S, Ziino O, et al., Infection Study Group of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation. Haematologica 2010; 95:1612-1615.
41. Trecarichi EM, Tumbarello M, Caira M, et al. Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica 2011; 96:e1-e3.
42. Cattaneo C, Antoniazzi F, Casari S, et al. P. aeruginosa bloodstream infections among hematological patients: an old or new question? Ann Hematol 2012; 91:1299-1304.
43. Ansari SR, Hanna H, Hachem R, et al. Risk factors for infections with multidrug-resistant Stenotrophomonas maltophilia in patients with cancer. Cancer 2007; 109:2615-2622.
44. Gafter-Gvili A, Fraser A, Paul M, Leibovici L.Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142:979e95.
45. Trecarichi EM, Cauda R, Tumbarello M. Detecting risk and predicting patient mortality in patients with extended-spectrum b-lactamase-producing Enterobacteriaceae bloodstream infections. Future Microbiol 2012; 7:1173-1189.
46. Viale P, Giannella M, Lewis R, et al. Predictors of mortality in multidrugresistant Klebsiella pneumoniae bloodstream infections. Expert Rev Anti Infect Ther 2013; 11:1053-1063.
47. Bow EJ. Fluoroquinolones antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis 2011; 24:545-553.
48. Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother 2007; 59:5-22.
49. Chong Y, Yakushiji H, Ito Y, Kamimura T. Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies. Int J Infect Dis 2011; 15:e277-e281.
50. Saito T, Yoshioka S, Iinuma Y, et al. Effects on spectrum and susceptibility patterns of isolates causing bloodstream infection by restriction of fluoroquinolone prophylaxis in a hematology-oncology unit. Eur J Clin Microbiol Infect Dis 2008; 27:209-216.
51. Rangaraj G, Granwehr BP, Jiang Y, et al. Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms. Cancer 2010; 116:967-973.
52. Tumbarello M, Repetto E, Trecarichi EM, et al. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality. Epidemiol Infect 2011; 139:1740-1749.
53. Tumbarello M, Spanu T, Di Bidino R, et al. Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta- lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother 2010; 54:4085-4091.
54. Giske CG, Monnet DL, Cars O, Carmeli Y, ReAct-Action on Antibiotic Resistance. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008; 52:813-821.
55. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55: 943-950.
56. Satlin MJ, Calfee DP, Chen L, et al. Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leuk Lymphoma 2013; 54:799-806.